Cyprotex Trading Update
13 December 2012 – Cyprotex PLC (AIM:CRX), the preclinical ADME-Tox services company, today provides an update on trading following the Company’s interim results on 6 September 2012.
For the first half of the year, Cyprotex announced a 5.1% increase in revenues to £3.72m with an operating loss of £189,000. While revenues up to the month of October were as expected, late November and December performance have been slightly softer than expected due to a delay in customers sending the compounds prior to the extended Christmas holiday period.
Revenues are ahead of 2011 comparables and the Company continues to trade profitably, however, we expect revenues will be slightly below market expectations with a commensurate drop in profit.
For further information:
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Office
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
N+1 Singer (Nomad and broker to Cyprotex)
Tel: +44 (0)20 7496 3000
Tel: +44 (0) 20 7831 3113
Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683